{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:11:36Z","timestamp":1789704696102,"version":"4.0.1"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":2165,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T00:00:00Z","timestamp":1579824000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K01OD020153-01A1"],"award-info":[{"award-number":["K01OD020153-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007015","name":"University of Wisconsin-Madison","doi-asserted-by":"publisher","award":["Start-up funds"],"award-info":[{"award-number":["Start-up funds"]}],"id":[{"id":"10.13039\/100007015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K01OD020153\u201001A1"],"award-info":[{"award-number":["K01OD020153\u201001A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007015","name":"University of Wisconsin-Madison","doi-asserted-by":"publisher","award":["Start\u2010up funds"],"award-info":[{"award-number":["Start\u2010up funds"]}],"id":[{"id":"10.13039\/100007015","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There is no widely accepted standard medical treatment for apocrine gland anal sac adenocarcinoma (AGASACA) in dogs. Targeted agents such as toceranib may be effective in treatment of AGASACA, but the number of clinical reports investigating its efficacy is limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Hypothesis\/Aim<\/jats:title>\n                    <jats:p>To evaluate the efficacy of toceranib treatment of AGASACA in dogs, and to assess prognostic factors in the study population. Our hypothesis was that toceranib would provide a clinical benefit in the treatment of dogs with AGASACA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Animals<\/jats:title>\n                    <jats:p>Thirty-six client-owned dogs with either a cytologic or histologic diagnosis of AGASACA that were treated with toceranib alone or in combination with surgery, nonconcurrent chemotherapy or both.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Result<\/jats:title>\n                    <jats:p>The median progression-free survival (PFS) and overall survival time (OST) for the study population was 313\u2009days and 827\u2009days, respectively. A clinical benefit from toceranib treatment was observed in 69% of dogs, with 20.7% of dogs experiencing partial response and 48.3% of dogs experiencing stable disease. Dogs that responded to toceranib treatment had significantly prolonged PFS and OST. Hypercalcemia was a negative prognostic factor for clinical outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Toceranib is effective in the treatment of AGASACA in dogs. Prospective, controlled clinical trials are needed to determine the efficacy of toceranib in comparison to other treatment protocols for dogs with AGASACA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jvim.15706","type":"journal-article","created":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T08:49:27Z","timestamp":1579855767000},"page":"873-881","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Evaluation of toceranib for treatment of apocrine gland anal sac adenocarcinoma in dogs"],"prefix":"10.1093","volume":"34","author":[{"given":"Caitlin M.","family":"Heaton","sequence":"first","affiliation":[{"name":"School of Veterinary Medicine, University of Wisconsin-Madison Department of Medical Sciences, , Madison, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur F. A.","family":"Fernandes","sequence":"additional","affiliation":[{"name":"Animal Sciences, University of Wisconsin-Madison , Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo C.","family":"Jark","sequence":"additional","affiliation":[{"name":"School of Veterinary Medicine, University of Wisconsin-Madison Department of Medical Sciences, , Madison, Wisconsin"},{"name":"Universidade Estadual Paulista Julio de Mesquita Filho-Campus de Jaboticabal , Jaboticabal, SP,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8308-8495","authenticated-orcid":false,"given":"Xuan","family":"Pan","sequence":"additional","affiliation":[{"name":"School of Veterinary Medicine, University of Wisconsin-Madison Department of Medical Sciences, , Madison, Wisconsin"},{"name":"Carbone Cancer Center, University of Wisconsin-Madison , Madison, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,3,1]]},"reference":[{"key":"2026020302533700200_jvim15706-bib-0001","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/j.1439-0442.1989.tb00787.x","article-title":"Canine perineal tumours","volume":"36","author":"Berrocal","year":"1989","journal-title":"J Vet Med Ser A"},{"key":"2026020302533700200_jvim15706-bib-0002","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1748-5827.1981.tb00591.x","article-title":"Anal sac gland adenocarcinoma in the dog: 14 cases","volume":"22","author":"Goldschmidt","year":"1981","journal-title":"J Small Anim Pract"},{"key":"2026020302533700200_jvim15706-bib-0003","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1939-1676.2002.tb01613.x","article-title":"Canine anal sac adenocarcinomas: clinical presentation and response to therapy","volume":"16","author":"Bennett","year":"2002","journal-title":"J Vet Intern Med"},{"key":"2026020302533700200_jvim15706-bib-0004","doi-asserted-by":"crossref","first-page":"825","DOI":"10.2460\/javma.2003.223.825","article-title":"Carcinoma of the apocrine glands of the anal sac in dogs: 113 cases (1985-1995)","volume":"223","author":"Williams","year":"2003","journal-title":"J Am Vet Med Assoc"},{"key":"2026020302533700200_jvim15706-bib-0005","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1046\/j.1476-5829.2003.00013.x","article-title":"Postoperative radiotherapy and mitoxantrone for anal sac adenocarcinoma in the dog: 15 cases (1991-2001)","volume":"1","author":"Turek","year":"2003","journal-title":"Vet Comp Oncol"},{"key":"2026020302533700200_jvim15706-bib-0006","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/j.1751-0813.2005.tb15626.x","article-title":"Anal sac tumours of the dog and their response to cytoreductive surgery and chemotherapy","volume":"83","author":"Emms","year":"2005","journal-title":"Aust Vet J"},{"key":"2026020302533700200_jvim15706-bib-0007","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1532-950X.2006.00137.x","article-title":"Surgery of metastatic anal sac adenocarcinoma in five dogs","volume":"35","author":"Hobson","year":"2006","journal-title":"Vet Surg"},{"key":"2026020302533700200_jvim15706-bib-0008","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/vco.12068","article-title":"Evaluation of adjuvant carboplatin chemotherapy in the management of surgically excised anal sac apocrine gland adenocarcinoma in dogs","volume":"14","author":"Wouda","year":"2016","journal-title":"Vet Comp Oncol"},{"key":"2026020302533700200_jvim15706-bib-0009","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1939-1676.1994.tb03224.x","article-title":"Treatment of tumor-bearing dogs with actinomycin D","volume":"8","author":"Hammer","year":"1994","journal-title":"J Vet Intern Med"},{"key":"2026020302533700200_jvim15706-bib-0010","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.1158\/1078-0432.CCR-08-1860","article-title":"Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision","volume":"15","author":"London","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2026020302533700200_jvim15706-bib-0011","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1182\/blood-2001-12-0350","article-title":"Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors","volume":"100","author":"Liao","year":"2002","journal-title":"Blood"},{"key":"2026020302533700200_jvim15706-bib-0012","first-page":"2755","article-title":"Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies","volume":"9","author":"London","year":"2003","journal-title":"Clin Cancer Res"},{"key":"2026020302533700200_jvim15706-bib-0013","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","article-title":"Cell signaling by receptor tyrosine kinases","volume":"141","author":"Lemmon","year":"2010","journal-title":"Cell"},{"key":"2026020302533700200_jvim15706-bib-0014","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jcpa.2009.06.004","article-title":"Expression of vascular endothelial growth factor in canine inflammatory and non-inflammatory mammary carcinoma","volume":"142","author":"Millanta","year":"2010","journal-title":"J Comp Pathol"},{"key":"2026020302533700200_jvim15706-bib-0015","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1053\/jcpa.2000.0404","article-title":"Expression of vascular endothelial growth factor in basal cell tumours and in squamous cell carcinomas of canine skin","volume":"123","author":"Maiolino","year":"2000","journal-title":"J Comp Pathol"},{"key":"2026020302533700200_jvim15706-bib-0016","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1354\/vp.39-4-488","article-title":"Expression of vascular endothelial growth factor in canine mammary tumors","volume":"39","author":"Restucci","year":"2002","journal-title":"Vet Pathol"},{"key":"2026020302533700200_jvim15706-bib-0017","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.rvsc.2006.01.007","article-title":"The role of vascular endothelial growth factor and its receptor Flk-1\/KDR in promoting tumour angiogenesis in feline and canine mammary carcinomas: a preliminary study of autocrine and paracrine loops","volume":"81","author":"Millanta","year":"2006","journal-title":"Res Vet Sci"},{"key":"2026020302533700200_jvim15706-bib-0018","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1476-5829.2008.00178.x","article-title":"Expression of epidermal growth factor receptor and vascular endothelial growth factor in malignant canine epithelial nasal tumours","volume":"7","author":"Shiomitsu","year":"2009","journal-title":"Vet Comp Oncol"},{"key":"2026020302533700200_jvim15706-bib-0019","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1354\/vp.44-6-823","article-title":"Immunohistochemical expression of vascular endothelial growth factor and vascular endothelial growth factor receptor associated with tumor cell proliferation in canine cutaneous squamous cell carcinomas and trichoepitheliomas","volume":"44","author":"Al-Dissi","year":"2007","journal-title":"Vet Pathol"},{"key":"2026020302533700200_jvim15706-bib-0020","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1354\/vp.43-6-971","article-title":"Expression of vascular endothelial growth factor, basic fibroblast growth factor, and their receptors (flt-1, flk-1, and flg-1) in canine vascular tumors","volume":"43","author":"Yonemaru","year":"2006","journal-title":"Vet Pathol"},{"key":"2026020302533700200_jvim15706-bib-0021","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/j.1939-1676.2006.tb02912.x","article-title":"Vascular endothelial growth factor expression in canine intracranial meningiomas and association with patient survival","volume":"20","author":"Platt","year":"2006","journal-title":"J Vet Intern Med"},{"key":"2026020302533700200_jvim15706-bib-0022","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.vetimm.2006.11.009","article-title":"Detection of vascular endothelial growth factor (VEGF) and VEGF receptors Flt-1 and KDR in canine mastocytoma cells","volume":"115","author":"Rebuzzi","year":"2007","journal-title":"Vet Immunol Immunopathol"},{"key":"2026020302533700200_jvim15706-bib-0023","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jcpa.2009.05.004","article-title":"Immunohistochemical expression of vascular endothelial growth factor and vascular endothelial growth factor receptor in canine cutaneous fibrosarcomas","volume":"141","author":"Al-Dissi","year":"2009","journal-title":"J Comp Pathol"},{"key":"2026020302533700200_jvim15706-bib-0024","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1476-5829.2011.00275.x","article-title":"Preliminary evidence for biologic activity of toceranib phosphate (Palladia((R))) in solid tumours","volume":"10","author":"London","year":"2012","journal-title":"Vet Comp Oncol"},{"key":"2026020302533700200_jvim15706-bib-0025","doi-asserted-by":"crossref","first-page":"960","DOI":"10.2460\/javma.254.8.960","article-title":"Response and outcome following toceranib phosphate treatment for stage four anal sac apocrine gland adenocarcinoma in dogs: 15 cases (2013-2017)","volume":"254","author":"Elliott","year":"2019","journal-title":"J Am Vet Med Assoc"},{"key":"2026020302533700200_jvim15706-bib-0026","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/vco.12032","article-title":"Response evaluation criteria for solid tumours in dogs (v1.0): a Veterinary Cooperative Oncology Group (VCOG) consensus document","volume":"13","author":"Nguyen","year":"2015","journal-title":"Vet Comp Oncol"},{"key":"2026020302533700200_jvim15706-bib-0027","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1476-5810.2004.0053b.x","article-title":"Veterinary Co-operative Oncology Group - common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0","volume":"2","author":"Veterinary Co-operative Oncology G","year":"2004","journal-title":"Vet Comp Oncol"},{"key":"2026020302533700200_jvim15706-bib-0028","author":"Team RC","year":"2017"},{"key":"2026020302533700200_jvim15706-bib-0029","author":"Therneau"},{"key":"2026020302533700200_jvim15706-bib-0030","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1939-1676.2007.tb02960.x","article-title":"Clinical stage, therapy, and prognosis in canine anal sac gland carcinoma","volume":"21","author":"Polton","year":"2007","journal-title":"J Vet Intern Med"},{"key":"2026020302533700200_jvim15706-bib-0031","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMp068070","article-title":"The challenge of subgroup analyses: reporting without distorting","volume":"354","author":"Lagakos","year":"2006","journal-title":"N Engl J Med"},{"key":"2026020302533700200_jvim15706-bib-0032","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/1746-6148-9-190","article-title":"Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose","volume":"9","author":"Bernabe","year":"2013","journal-title":"BMC Vet Res"},{"key":"2026020302533700200_jvim15706-bib-0033","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2460\/javma.253.1.84","article-title":"Outcome and clinical, pathological, and immunohistochemical factors associated with prognosis for dogs with early-stage anal sac adenocarcinoma treated with surgery alone: 34 cases (2002-2013)","volume":"253","author":"Skorupski","year":"2018","journal-title":"J Am Vet Med Assoc"},{"key":"2026020302533700200_jvim15706-bib-0034","doi-asserted-by":"crossref","first-page":"877","DOI":"10.2460\/javma.246.8.877","article-title":"Surgical excision of anal sac apocrine gland adenocarcinomas with and without adjunctive chemotherapy in dogs: 42 cases (2005-2011)","volume":"246","author":"Potanas","year":"2015","journal-title":"J Am Vet Med Assoc"},{"key":"2026020302533700200_jvim15706-bib-0035","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/jsap.12633","article-title":"Surgical management of primary, metastatic and recurrent anal sac adenocarcinoma in the dog: 52 cases","volume":"58","author":"Barnes","year":"2017","journal-title":"J Small Anim Pract"}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvim.15706","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvim.15706","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jvim.15706","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/34\/2\/873\/66660720\/jvim15706.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/34\/2\/873\/66660720\/jvim15706.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T07:53:50Z","timestamp":1770105230000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/34\/2\/873\/8448297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,1]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,3,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jvim.15706","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,3]]},"published":{"date-parts":[[2020,3,1]]},"assertion":[{"value":"2019-06-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}